Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.
Draghi A, Presti M, Jensen AWP, Chamberlain CA, Albieri B, Rasmussen AK, Andersen MH, Crowther MD, Svane IM, Donia M. Draghi A, et al. Among authors: chamberlain ca. Clin Cancer Res. 2023 Oct 2;29(19):3937-3947. doi: 10.1158/1078-0432.CCR-22-3853. Clin Cancer Res. 2023. PMID: 37126006
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen IM, Donia M, Chamberlain CA, Jensen AWP, Draghi A, Theile S, Madsen K, Hasselby JP, Toxværd A, Høgdall E, Lorentzen T, Wilken EE, Geertsen P, Svane IM, Johansen JS, Nielsen D. Chen IM, et al. Among authors: chamberlain ca. Eur J Cancer. 2023 Feb;180:125-133. doi: 10.1016/j.ejca.2022.11.035. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36592507 Free article. Clinical Trial.
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Nielsen M, et al. Among authors: chamberlain ca. Cancer Immunol Res. 2022 Oct 4;10(10):1254-1262. doi: 10.1158/2326-6066.CIR-22-0326. Cancer Immunol Res. 2022. PMID: 35969233
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens.
Draghi A, Chamberlain CA, Khan S, Papp K, Lauss M, Soraggi S, Radic HD, Presti M, Harbst K, Gokuldass A, Kverneland A, Nielsen M, Westergaard MCW, Andersen MH, Csabai I, Jönsson G, Szallasi Z, Svane IM, Donia M. Draghi A, et al. Among authors: chamberlain ca. Front Immunol. 2021 Oct 11;12:705422. doi: 10.3389/fimmu.2021.705422. eCollection 2021. Front Immunol. 2021. PMID: 34707600 Free PMC article.
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Kverneland AH, Chamberlain CA, Borch TH, Nielsen M, Mørk SK, Kjeldsen JW, Lorentzen CL, Jørgensen LP, Riis LB, Yde CW, Met Ö, Donia M, Svane IM. Kverneland AH, et al. Among authors: chamberlain ca. J Immunother Cancer. 2021 Oct;9(10):e003499. doi: 10.1136/jitc-2021-003499. J Immunother Cancer. 2021. PMID: 34607899 Free PMC article.
Transcriptomic signatures of tumors undergoing T cell attack.
Gokuldass A, Schina A, Lauss M, Harbst K, Chamberlain CA, Draghi A, Westergaard MCW, Nielsen M, Papp K, Sztupinszki Z, Csabai I, Svane IM, Szallasi Z, Jönsson G, Donia M. Gokuldass A, et al. Among authors: chamberlain ca. Cancer Immunol Immunother. 2022 Mar;71(3):553-563. doi: 10.1007/s00262-021-03015-1. Epub 2021 Jul 17. Cancer Immunol Immunother. 2022. PMID: 34272988 Free PMC article.
29 results